IGC PHARMA, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
IGC PHARMA, INC. (IGC) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $750.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-14
- IGC PHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $750.00K, a 50.60% increase year-over-year.
- IGC PHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $1.02M, a 122.93% increase year-over-year.
- IGC PHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-12-31 was $975.00K, a 153.91% increase year-over-year.
- IGC PHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $742.00K, a 70.97% increase year-over-year.
- IGC PHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $1.71M, a 10.85% decline from fiscal 2024.
- IGC PHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $1.92M, a 32.57% decline from fiscal 2023.
- IGC PHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $2.84M, a 29.40% increase from fiscal 2022.
- IGC PHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $2.20M, a 210.31% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $750.00K 10-Q · filed 2026-08-14 | $1.77M 10-Q · filed 2026-08-14 | $2.75M derived: sum of 3 quarters · filed 2026-08-14 | $3.49M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $1.02M 10-Q · filed 2026-05-15 | $2.00M derived: sum of 2 quarters · filed 2026-05-15 | $2.74M derived: sum of 3 quarters · filed 2026-05-15 | $3.24M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $975.00K derived: 10-KT 9 month − 10-Q 6 month · filed 2026-03-18 | $1.72M derived: sum of 2 quarters · filed 2026-03-18 | $2.21M 10-KT · filed 2026-03-18 | $2.67M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-09-30 | $742.00K 10-Q · filed 2025-11-14 | $1.24M 10-Q · filed 2025-11-14 | $1.70M derived: sum of 3 quarters · filed 2026-08-14 | $2.08M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $498.00K 10-Q · filed 2026-08-14 | $956.00K 10-Q · filed 2026-08-14 | $1.34M derived: sum of 3 quarters · filed 2026-08-14 | $1.77M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $458.00K 10-Q · filed 2026-05-15 | $842.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.28M derived: sum of 3 quarters · filed 2026-05-15 | $1.71M 10-KT · filed 2026-03-18 | |
| 2024-12-31 | $384.00K 10-Q · filed 2025-02-14 | $818.00K derived: sum of 2 quarters · filed 2025-11-14 | $1.25M 10-Q · filed 2025-02-14 | $1.74M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-09-30 | $434.00K 10-Q · filed 2025-11-14 | $867.00K 10-Q · filed 2025-11-14 | $1.35M derived: sum of 3 quarters · filed 2025-11-14 | $1.88M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $433.00K 10-Q · filed 2025-08-14 | $917.00K derived: sum of 2 quarters · filed 2025-08-14 | $1.44M derived: sum of 3 quarters · filed 2025-08-14 | $1.99M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $484.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-27 | $1.01M derived: sum of 2 quarters · filed 2025-06-27 | $1.56M derived: sum of 3 quarters · filed 2025-06-27 | $1.92M 10-K · filed 2025-06-27 | |
| 2023-12-31 | $526.00K 10-Q · filed 2025-02-14 | $1.08M derived: sum of 2 quarters · filed 2025-02-14 | $1.43M 10-Q · filed 2025-02-14 | $2.02M derived: sum of 4 quarters · filed 2025-02-14 | |
| 2023-09-30 | $550.00K 10-Q · filed 2024-11-12 | $907.00K 10-Q · filed 2024-11-12 | $1.49M derived: sum of 3 quarters · filed 2024-11-12 | $1.97M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $357.00K 10-Q · filed 2024-08-07 | $940.00K derived: sum of 2 quarters · filed 2024-08-07 | $1.42M derived: sum of 3 quarters · filed 2024-08-07 | $2.05M derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | $583.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-24 | $1.07M derived: sum of 2 quarters · filed 2024-06-24 | $1.69M derived: sum of 3 quarters · filed 2024-06-24 | $2.84M 10-K · filed 2024-06-24 | |
| 2022-12-31 | $483.00K 10-Q · filed 2024-02-14 | $1.11M derived: sum of 2 quarters · filed 2024-02-14 | $2.26M 10-Q · filed 2024-02-14 | $3.38M derived: sum of 4 quarters · filed 2024-02-14 | |
| 2022-09-30 | $624.00K 10-Q · filed 2023-11-09 | $1.78M 10-Q · filed 2023-11-09 | $2.90M derived: sum of 3 quarters · filed 2023-11-09 | $3.42M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $1.15M 10-Q · filed 2023-08-10 | $2.28M derived: sum of 2 quarters · filed 2023-08-10 | $2.80M derived: sum of 3 quarters · filed 2023-08-10 | $3.22M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-07 | $1.65M derived: sum of 2 quarters · filed 2023-07-07 | $2.07M derived: sum of 3 quarters · filed 2023-07-07 | $2.20M 10-K · filed 2023-07-07 | |
| 2021-12-31 | $523.00K 10-Q · filed 2023-02-14 | $947.00K derived: sum of 2 quarters · filed 2023-02-14 | $1.07M 10-Q · filed 2023-02-14 | $1.21M derived: sum of 4 quarters · filed 2023-02-14 | |
| 2021-09-30 | $424.00K 10-Q · filed 2022-11-01 | $549.00K 10-Q · filed 2022-11-01 | $684.00K derived: sum of 3 quarters · filed 2022-11-01 | $841.00K derived: sum of 4 quarters · filed 2022-11-01 | |
| 2021-06-30 | $125.00K 10-Q · filed 2022-08-05 | $260.00K derived: sum of 2 quarters · filed 2022-08-05 | $417.00K derived: sum of 3 quarters · filed 2022-08-05 | $667.00K derived: sum of 4 quarters · filed 2022-08-05 | |
| 2021-03-31 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-23 | $292.00K derived: sum of 2 quarters · filed 2022-06-23 | $542.00K derived: sum of 3 quarters · filed 2022-06-23 | $708.00K 10-K · filed 2022-06-23 | |
| 2020-12-31 | $157.00K 10-Q · filed 2022-02-10 | $407.00K derived: sum of 2 quarters · filed 2022-02-10 | $573.00K 10-Q · filed 2022-02-10 | $742.00K derived: sum of 4 quarters · filed 2022-02-10 | |
| 2020-09-30 | $250.00K 10-Q · filed 2021-10-29 | $416.00K 10-Q · filed 2021-10-29 | $585.00K derived: sum of 3 quarters · filed 2021-10-29 | $775.00K derived: sum of 4 quarters · filed 2021-10-29 | |
| 2020-06-30 | $166.00K 10-Q · filed 2021-08-11 | $335.00K derived: sum of 2 quarters · filed 2021-08-11 | $525.00K derived: sum of 3 quarters · filed 2021-08-11 | $669.00K derived: sum of 4 quarters · filed 2021-08-11 | |
| 2020-03-31 | $169.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-14 | $359.00K derived: sum of 2 quarters · filed 2021-06-14 | $503.00K derived: sum of 3 quarters · filed 2021-06-14 | $711.00K 10-K · filed 2021-06-14 | |
| 2019-12-31 | $190.00K 10-Q · filed 2021-02-16 | $334.00K derived: sum of 2 quarters · filed 2021-02-16 | $542.00K 10-Q · filed 2021-02-16 | -$1.77M derived: sum of 4 quarters · filed 2021-02-16 | |
| 2019-09-30 | $144.00K 10-Q · filed 2020-11-20 | $352.00K 10-Q · filed 2020-11-20 | -$1.96M derived: sum of 3 quarters · filed 2020-11-20 | -$1.88M derived: sum of 4 quarters · filed 2020-11-20 | |
| 2019-06-30 | $208.00K 10-Q · filed 2020-08-19 | -$2.10M derived: sum of 2 quarters · filed 2020-08-19 | -$2.02M derived: sum of 3 quarters · filed 2020-08-19 | $666.00K derived: sum of 4 quarters · filed 2020-08-19 | |
| 2019-03-31 | -$2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2020-07-13 | -$2.23M derived: sum of 2 quarters · filed 2020-07-13 | $458.00K derived: sum of 3 quarters · filed 2020-07-13 | $638.00K 10-K · filed 2020-07-13 | |
| 2018-12-31 | $80.00K 10-Q · filed 2020-02-10 | $2.77M derived: sum of 2 quarters · filed 2020-02-10 | $2.95M 10-Q · filed 2020-02-10 | ||
| 2018-09-30 | $2.69M 10-Q · filed 2019-11-06 | $2.87M 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | $179.00K 10-Q · filed 2019-08-09 | ||||
| 2018-03-31 | $659.00K 10-K · filed 2019-06-14 | $352.24K 10-K · filed 2018-06-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |